CD33 and acute myeloid leukemia: Even with recent advances in the treatment of AML with targeted therapies such as the BCL2 inhibitor venetoclax and the CD33 inhibitor gemtuzumab ozogamicin, the prognosis for AML patients remains poor, with a cure rate of only 40% for patients under the age of 60 and as low as 15% for patients 60 years and older,10, 11 a grim outlook for a disease with a median age of diagnosis of 68 years.4